← Back to Search

Unknown

EDP-235 SAD Cohorts for COVID-19

Phase 1
Waitlist Available
Research Sponsored by Enanta Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests a new drug called EDP-235 in healthy adults to see if it is safe and how the body handles it. Researchers will look at how the drug is processed in the body and check for any side effects.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2023 Phase 2 trial • 231 Patients • NCT05616728
1%
Hepatotoxicity
100%
80%
60%
40%
20%
0%
Study treatment Arm
EDP-235 200mg
EDP-235 400mg
Placebo

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: EDP-235 SAD CohortsExperimental Treatment1 Intervention
EDP-235 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5, orally, once daily in one single administration
Group II: EDP-235 MAD CohortsExperimental Treatment1 Intervention
EDP-235 Dose 1, Dose 2 and Dose 3 orally, once daily for 7 days
Group III: EDP-235 SAD Placebo CohortsPlacebo Group1 Intervention
Matching placebo, orally, once daily in one single administration
Group IV: EDP-235 MAD Placebo CohortsPlacebo Group1 Intervention
Matching placebo, orally, once daily for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EDP-235
2022
Completed Phase 2
~370

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Enanta PharmaceuticalsLead Sponsor
33 Previous Clinical Trials
2,282 Total Patients Enrolled
Enanta Pharmaceuticals, IncLead Sponsor
40 Previous Clinical Trials
3,049 Total Patients Enrolled
3 Trials studying COVID-19
291 Patients Enrolled for COVID-19
~19 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top